Premium
Programmed Release of Dihydroartemisinin for Synergistic Cancer Therapy Using a CaCO 3 Mineralized Metal–Organic Framework
Author(s) -
Wan Xiuyan,
Zhong Hui,
Pan Wei,
Li Yanhua,
Chen Yuanyuan,
Li Na,
Tang Bo
Publication year - 2019
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201907388
Subject(s) - chemistry , dihydroartemisinin , in vivo , photodynamic therapy , glutathione , cancer therapy , pharmacology , cancer cell , metal organic framework , cancer research , cancer , biophysics , biochemistry , artemisinin , medicine , organic chemistry , plasmodium falciparum , microbiology and biotechnology , adsorption , malaria , immunology , biology , enzyme
Dihydroartemisinin (DHA) has attracted increasing attention as an anticancer agent. However, using DHA to treat cancer usually depends on the synergistic effects of exogenous components, and the loss of DHA during delivery reduces its effectiveness in cancer therapy. Reported herein is a programmed release nanoplatform of DHA to synergistically treat cancer with a Fe‐TCPP [(4,4,4,4‐(porphine‐5,10,15,20‐tetrayl) tetrakis(benzoic acid)] NMOF (nanoscale MOF) having a CaCO 3 mineralized coating, which prevents DHA leakage during transport in the bloodstream. When the nanoplatform arrives at the tumor site, the weakly acidic microenvironment and high concentration of glutathione (GSH) trigger DHA release and TCPP activation, enabling the synergistic Fe 2+ ‐DHA‐mediated chemodynamic therapy, Ca 2+ ‐DHA‐mediated oncosis therapy, and TCPP‐mediated photodynamic therapy. In vivo experiments demonstrated that the nanoplatform showed enhanced anticancer efficiency and negligible toxicity.